Biodistribution of Neocarzinostatin Conjugated to Chimeric Fab Fragments of the Monoclonal Antibody A7 in Nude Mice Bearing Human Pancreatic Cancer Xenografts

6Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

In this study, we conjugated chimeric Fab fragments of the monoclonal antibody (MAb) A7, which reacts with pancreatic cancers, to the antitumor drug neocarzinostatin (chA7Fab‐NCS) and intravenously injected 125I‐labeled chA7Fab‐NCS into nude mice bearing a human pancreatic cancer xenograft. We compared the tumor localization of 125I‐labeled chA7Fab‐NCS with that of conventional 125I‐labeled A7‐NCS, which was produced by conjugation of MAb A7 and NCS. 125I‐Labeled chA7Fab‐NCS accumulated in the tumor earlier than 125I‐labeled A7‐NCS, and significantly larger amounts of 125I‐labeled chA7Fab‐NCS had accumulated in the tumor 1 hour after injection. The results suggest that chA7Fab may be a suitable carrier for NCS in immunotargeting therapy against pancreatic cancer. Copyright © 1994, Wiley Blackwell. All rights reserved

Cite

CITATION STYLE

APA

Otsuji, E., Yamaguchi, T., Yamaoka, N., Taniguchi, K., Kato, M., Kotani, T., … Takahashi, T. (1994). Biodistribution of Neocarzinostatin Conjugated to Chimeric Fab Fragments of the Monoclonal Antibody A7 in Nude Mice Bearing Human Pancreatic Cancer Xenografts. Japanese Journal of Cancer Research, 85(5), 530–535. https://doi.org/10.1111/j.1349-7006.1994.tb02391.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free